Cargando…
Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extraco...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123640/ https://www.ncbi.nlm.nih.gov/pubmed/21605394 http://dx.doi.org/10.1186/1471-2253-11-9 |
_version_ | 1782207009751302144 |
---|---|
author | Leino, Kari Hynynen, Markku Jalonen, Jouko Salmenperä, Markku Scheinin, Harry Aantaa, Riku |
author_facet | Leino, Kari Hynynen, Markku Jalonen, Jouko Salmenperä, Markku Scheinin, Harry Aantaa, Riku |
author_sort | Leino, Kari |
collection | PubMed |
description | BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extracorporeal circulation is a stressful procedure increasing sympathetic nervous system activity which could attenuate renal function due the interrelation of sympathetic nervous system, hemodynamics and renal function. We tested the hypothesis that dexmetomidine would improve kidney function in patients undergoing elective CABG during the first two postoperative days. METHODS: This was a double-blind, randomized, parallel-group study. Patients with normal renal function and scheduled for elective CABG were randomized to placebo or to infusion of dexmedetomidine to achieve a pseudo steady-state plasma concentration of 0.60 ng/ml. The infusion was started after anesthesia induction and continued until 4 h after surgery. The primary endpoint was creatinine clearance. Other variables included urinary creatinine and output, fractional sodium and potassium excretion, urinary potassium, sodium and glucose, serum and urinary osmolality and plasma catecholamine concentrations. The data were analyzed with repeated-measures ANOVA or Cochran-Mantel-Haenszel test. RESULTS: Sixty-six of 87 randomized patients were evaluable for analysis. No significant between-group differences were recorded for any indices of renal function except for a mean 74% increase in urinary output with dexmedetomidine in the first 4 h after insertion of a urinary catheter (p < 0.001). Confidence interval examination revealed that the sample size was large enough for the no-difference statement for creatinine clearance. CONCLUSIONS: Use of intravenous dexmedetomidine did not alter renal function in this cohort of relatively low-risk elective CABG patients but was associated with an increase in urinary output. This study was carried out in 1994-1997 and was thus not registered. |
format | Online Article Text |
id | pubmed-3123640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31236402011-06-26 Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study Leino, Kari Hynynen, Markku Jalonen, Jouko Salmenperä, Markku Scheinin, Harry Aantaa, Riku BMC Anesthesiol Research Article BACKGROUND: Dexmedetomidine, an alpha(2)-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extracorporeal circulation is a stressful procedure increasing sympathetic nervous system activity which could attenuate renal function due the interrelation of sympathetic nervous system, hemodynamics and renal function. We tested the hypothesis that dexmetomidine would improve kidney function in patients undergoing elective CABG during the first two postoperative days. METHODS: This was a double-blind, randomized, parallel-group study. Patients with normal renal function and scheduled for elective CABG were randomized to placebo or to infusion of dexmedetomidine to achieve a pseudo steady-state plasma concentration of 0.60 ng/ml. The infusion was started after anesthesia induction and continued until 4 h after surgery. The primary endpoint was creatinine clearance. Other variables included urinary creatinine and output, fractional sodium and potassium excretion, urinary potassium, sodium and glucose, serum and urinary osmolality and plasma catecholamine concentrations. The data were analyzed with repeated-measures ANOVA or Cochran-Mantel-Haenszel test. RESULTS: Sixty-six of 87 randomized patients were evaluable for analysis. No significant between-group differences were recorded for any indices of renal function except for a mean 74% increase in urinary output with dexmedetomidine in the first 4 h after insertion of a urinary catheter (p < 0.001). Confidence interval examination revealed that the sample size was large enough for the no-difference statement for creatinine clearance. CONCLUSIONS: Use of intravenous dexmedetomidine did not alter renal function in this cohort of relatively low-risk elective CABG patients but was associated with an increase in urinary output. This study was carried out in 1994-1997 and was thus not registered. BioMed Central 2011-05-23 /pmc/articles/PMC3123640/ /pubmed/21605394 http://dx.doi.org/10.1186/1471-2253-11-9 Text en Copyright ©2011 Leino et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Leino, Kari Hynynen, Markku Jalonen, Jouko Salmenperä, Markku Scheinin, Harry Aantaa, Riku Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title | Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title_full | Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title_fullStr | Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title_full_unstemmed | Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title_short | Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
title_sort | renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123640/ https://www.ncbi.nlm.nih.gov/pubmed/21605394 http://dx.doi.org/10.1186/1471-2253-11-9 |
work_keys_str_mv | AT leinokari renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy AT hynynenmarkku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy AT jalonenjouko renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy AT salmenperamarkku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy AT scheininharry renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy AT aantaariku renaleffectsofdexmedetomidineduringcoronaryarterybypasssurgeryarandomizedplacebocontrolledstudy |